Reynisdottir, I.; Arason, A.; Freysteinsdottir, E.S.; Kristjansdottir, S.B.; Hilmarsdottir, B.; Traustadottir, G.A.; Johannsson, O.T.; Agnarsson, B.A.; Barkardottir, R.B.
High Atlastin 2-2 (ATL2-2) Expression Associates with Worse Prognosis in Estrogen-Receptor-Positive Breast Cancer. Genes 2023, 14, 1559.
https://doi.org/10.3390/genes14081559
AMA Style
Reynisdottir I, Arason A, Freysteinsdottir ES, Kristjansdottir SB, Hilmarsdottir B, Traustadottir GA, Johannsson OT, Agnarsson BA, Barkardottir RB.
High Atlastin 2-2 (ATL2-2) Expression Associates with Worse Prognosis in Estrogen-Receptor-Positive Breast Cancer. Genes. 2023; 14(8):1559.
https://doi.org/10.3390/genes14081559
Chicago/Turabian Style
Reynisdottir, Inga, Adalgeir Arason, Edda S. Freysteinsdottir, Sigrun B. Kristjansdottir, Bylgja Hilmarsdottir, Gunnhildur A. Traustadottir, Oskar T. Johannsson, Bjarni A. Agnarsson, and Rosa B. Barkardottir.
2023. "High Atlastin 2-2 (ATL2-2) Expression Associates with Worse Prognosis in Estrogen-Receptor-Positive Breast Cancer" Genes 14, no. 8: 1559.
https://doi.org/10.3390/genes14081559
APA Style
Reynisdottir, I., Arason, A., Freysteinsdottir, E. S., Kristjansdottir, S. B., Hilmarsdottir, B., Traustadottir, G. A., Johannsson, O. T., Agnarsson, B. A., & Barkardottir, R. B.
(2023). High Atlastin 2-2 (ATL2-2) Expression Associates with Worse Prognosis in Estrogen-Receptor-Positive Breast Cancer. Genes, 14(8), 1559.
https://doi.org/10.3390/genes14081559